Super-enhancers (SEs) consist of enhancer clusters with abundant binding of transcription factors (TFs) and cofactors. LSD1 is a histone modifier that eliminates SE activity. However, whether SE suppression by LSD1 is associated with leukemogenesis remains unknown. In erythro-megakaryocyte lineage leukemia cells, activation of the SE of GFI1 (GFI1-SE) is related to induction of myeloid differentiation by LSD1 inhibitors NCD38 and NCD25 and to their antileukemia effect. Although functional TF-motifs were concentrated in an evolutionally conserved area, NCD38 barely induced additional TF recruitment. Instead, the transcription cofactors including LSD1, CoREST, HDAC1, and HDAC2 were evicted from GFI1-SE. Deletion of GFI1-SE impaired induction ...
Acute promyelocytic leukemia (APL) is characterized by the appearance of blasts, insensitive to phys...
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy characterized by the accumu...
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the ra...
Summary: Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leuke...
Lysine (K)-specific demethylase 1A (LSD1/KDM1A) has been identified as a potential therapeutic targe...
Yidi Guo,1 Xueqi Fu,1,2 Yue Jin,1 Jing Sun,1 Ye Liu,1 Bo Huo,1 Xiang Li,1 Xin Hu1–31School of ...
Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in...
Mutations in Fms-like tyrosine kinase 3 (FLT3) are common drivers in acute myeloid leukemia (AML) ye...
Previous studies elucidated that LSD1(Lysine Specific Demethylase1)/KDM1A (Lysine Demethylase 1A), a...
The histone demethylase LSD1 is over-expressed in hematological tumors and has emerged as a promisin...
Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying ep...
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especia...
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the ra...
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are...
dissertationCell differentiation requires precise genetic regulation by transcription factors, their...
Acute promyelocytic leukemia (APL) is characterized by the appearance of blasts, insensitive to phys...
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy characterized by the accumu...
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the ra...
Summary: Pharmacologic inhibition of LSD1 promotes blast cell differentiation in acute myeloid leuke...
Lysine (K)-specific demethylase 1A (LSD1/KDM1A) has been identified as a potential therapeutic targe...
Yidi Guo,1 Xueqi Fu,1,2 Yue Jin,1 Jing Sun,1 Ye Liu,1 Bo Huo,1 Xiang Li,1 Xin Hu1–31School of ...
Pharmacologic inhibition of LSD1 induces molecular and morphologic differentiation of blast cells in...
Mutations in Fms-like tyrosine kinase 3 (FLT3) are common drivers in acute myeloid leukemia (AML) ye...
Previous studies elucidated that LSD1(Lysine Specific Demethylase1)/KDM1A (Lysine Demethylase 1A), a...
The histone demethylase LSD1 is over-expressed in hematological tumors and has emerged as a promisin...
Complex regulatory networks control epithelial-to-mesenchymal transition (EMT) but the underlying ep...
There is an unmet need to overcome nongenetic therapy-resistance to improve outcomes in AML, especia...
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the ra...
Culture conditions in which hematopoietic stem cells (HSCs) can be expanded for clinical benefit are...
dissertationCell differentiation requires precise genetic regulation by transcription factors, their...
Acute promyelocytic leukemia (APL) is characterized by the appearance of blasts, insensitive to phys...
Acute myeloid leukemia (AML) is a heterogeneous hematopoietic malignancy characterized by the accumu...
The histone demethylase LSD1 is deregulated in several tumors, including leukemias, providing the ra...